News | June 10, 2014

Chemo-radionuclide Therapy Halts Neuroendocrine Cancer

Combined chemo and radionuclide therapy with radiosensitizing drugs slows or stops disease progression and leads to better patient survival

June 10, 2014 — Advanced cancer of the neuroendocrine system can lead to dismal prognoses, but a novel therapy is packing a punch by uniting powerful radionuclide treatment and chemotherapy drugs, revealed researchers at the Society of Nuclear Medicine and Molecular Imaging’s 2014 Annual Meeting.

The research findings show that the experimental therapy led to stabilization or regression of patients’ cancer in about 70 percent of cases a year after completion of the treatment, now called peptide receptor chemo-radionuclide therapy (PRCRT). The therapy is just catching on across Europe and Australia and now in U.S. clinical trials. 

“Results of this study suggest that PRCRT is a highly effective treatment option for patients with progressive NETs with high somatostatin receptor expression,” explained Grace Kong, MBBS, principal investigator for this study conducted at the Centre for Cancer Imaging, Peter MacCallum Cancer Centre in Melbourne, Australia.

Neuroendocrine tumors (NETs) are those that develop within a multiplicity of organs throughout the body that have nerve cells and interact with the endocrine system through chemical signaling made possible with various hormones. These tumors usually develop along the intestines and lungs, but they can also be found in the pancreas and many other sites, although rarely. For this study, researchers observed patients who had undergone at least three courses of treatment with Lutetium-177 DOTA-Octreotate, which is prescribed for inoperable patients with NETs expressing somatostatin hormone receptors. This study included a high proportion of grade two disease, which is more aggressive and associated with adverse prognosis. Researchers added a radio-sensitizing chemotherapy for 63 out of the 68 patients in the study.

All of these steps together produced encouraging responses in a majority of subjects, with 72 percent survival at two years. More than half of patients were still alive past the five-year mark after therapy.

“The high objective response and long median survival even in patients with more aggressive tumor biology warrant further studies comparing it with other targeted therapies recently approved, despite much lower response rates,” Kong added.

For more information: www.snmmi.org

Related Content

Videos | Radiation Therapy | August 13, 2018
ITN Editor Dave Fornell takes a tour of some of the innovative new technologies on the expo floor at the 2018 America
Videos | Radiation Therapy | August 13, 2018
A discussion with Mahadevappa Mahesh, MS, Ph.D., FAAPM, FACR, FACMP, FSCCT, professor of radiology and cardiology and
Videos | Proton Therapy | August 10, 2018
A discussion with Matthew Freeman, Ph.D., scientist at Los Alamos National Laboratory, New Mexico.
Videos | Radiomics | August 09, 2018
A discussion with Martin Vallieres, Ph.D., post-doctoral fellow at McGill University, Montreal, Canada.
Videos | AAPM | August 03, 2018
Ehsan Samei, Ph.D., DABR, FAAPM, FSPIE, director of the Duke Un...
Videos | Artificial Intelligence | August 01, 2018
A discussion with Steve Jiang, Ph.D., director of the medical...
Videos | Radiation Therapy | August 01, 2018
This is an example of how Cherenkov radiation glow can be collected with image intensifier cameras during radiotherap
Videos | AAPM | August 01, 2018
American Association of Physicists in Medicine (AAPM) President Bruce Thomadsen, M.D., professor of medical physics a
IBA Completes Installation of Two Proteus One Proton Therapy Systems in Japan
News | Proton Therapy | July 30, 2018
IBA (Ion Beam Applications S.A.) announced that they completed the first two installations of the Proteus One proton...
Overlay Init